Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.

导出 OA

翻译打印收藏纠错

第一作者： Paula,Dakin

第一单位： Global Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.

作者： Paula,Dakin ^[1] ; Alan J,Kivitz ^[2] ; Joseph S,Gimbel ^[3] ; Nebojsa,Skrepnik ^[4] ; Stephen J,DiMartino ^[1] ; Chetachi A,Emeremni ^[5] ; Haitao,Gao ^[5] ; Neil,Stahl ^[1] ; David M,Weinreich ^[1] ; George D,Yancopoulos ^[1] ; Gregory P,Geba ^[6]

作者单位： Global Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA. ^[1] Department of Rheumatology, Altoona Center for Research, Duncansville, Pennsylvania, USA. ^[2] Arizona Research Center, Phoenix, Arizona, USA. ^[3] Research Center, Tucson Orthopedic Institute, Tucson, Arizona, USA. ^[4] R&D, Regeneron Pharmaceuticals Inc, Basking Ridge, New Jersey, USA. ^[5] Global Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA gregory.geba@regeneron.com. ^[6]

关键词 analgesics fibromyalgis/pain syndromes low back pain osteoarthritis

主题词人类(Humans);双盲法(Double-Blind Method);腰痛(Low Back Pain);骨关节炎(Osteoarthritis);疼痛测定(Pain Measurement);治疗结果(Treatment Outcome)

DOI 10.1136/annrheumdis-2020-217259

PMID 33199274

发布时间 2022-12-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交